Free radicals in breast carcinogenesis, breast cancer progression and cancer stem cells. Biological bases to develop oxidative-based therapies

Critical Reviews in Oncology/Hematology

Volumn 80, Issue 3, 2011, Pages 347-368

  Vera Ramirez, Laura ^a   Sanchez Rovira, Pedro ^a   Ramirez Tortosa, M Carmen ^b,c   Ramirez Tortosa, Cesar L ^a   Granados Principal, Sergio ^b,c   Lorente, Jose A ^c   Quiles, Jose L ^b,c  

^a Complejo Hospitalario de Jaen ^*  (Spain)

^b Biomedical Research Center CIBM   (Spain)

^c UNIVERSITY OF GRANADA   (Spain)

Author keywords

Angiogenesis; Cancer stem cells; Metastasis; Oncogenesis; Oxidative stress

Indexed keywords

CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FREE RADICAL; GEMCITABINE; IRINOTECAN; METHOTREXATE; NAVELBINE; NITROGEN DIOXIDE; OXALIPLATIN; PACLITAXEL; PEMETREXED; PHOSPHOPROTEIN PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SINGLET OXYGEN; TENIPOSIDE; TOPOTECAN; TRANSCRIPTION FACTOR; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER INVASION; CANCER STEM CELL; CELL FUNCTION; CELL HETEROGENEITY; CELL RENEWAL; CYTOKINE PRODUCTION; DNA DAMAGE; DRUG DESIGN; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; MALIGNANT TRANSFORMATION; METASTASIS; NONHUMAN; ONCOGENE; OXIDATIVE STRESS; RESPIRATORY BURST; REVIEW; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; BREAST; BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; FEMALE; FREE RADICALS; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; OXIDATIVE STRESS;

EID: 80655124771     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2011.01.004     Document Type: Review

References (206)

1. Halliwell B., Gutteridge J.M.C. Free radicals in biology and medicine 1999, Oxford University Press, New York. 3rd ed.
2. Halliwell B. Reactive species and antioxidants. Redox biology is a fundamental theme of aerobic life. Plant Physiol 2006, 141:312-322.
3. Valko M., Leibfritz D., Moncol J., Cronin M.T.D., Mazur M., Tesler J. Free radicals and antioxidant in normal physiological functions and human disease. Int J Biochem Cell Biol 2007, 39:44-84.
4. Szatrowski T.P., Nathan C.F. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 1991, 51:794-798.
5. Evans M.D., Dizdaroglu M., Cooke M.S. Oxidative DNA damage and disease: induction, repair and significance. Mutat Res 2004, 567:1-61.
6. Pelicano H., Carney D., Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 2004, 7:97-110.
7. Quiles J.L., Farquharson A.J., Simpson D.K., Grant I., Wahle K.W. Olive oil phenolics: effects on DNA oxidation and redox enzyme mRNA in prostate cells. Br J Nutr 2002, 88:225-234.
8. Kang D.H. Oxidative stress, DNA damage, and breast cancer. AACN Clin Issues 2002, 13:540-549.
9. Olinski R., Gackowski D., Rozalski R., Foksinski M., Bialkowski K. Oxidative DNA damage in cancer patients: a cause or a consequence of the disease development?. Mutat Res 2003, 531:177-190.
10. Evans M.D., Cooke M.S. Factors contributing to the outcome of oxidative damage to nucleic acids. Bioessays 2004, 26:533-542.
11. Allen R.G., Tresini M. Oxidative stress and gene regulation. Free Radic Biol Med 2000, 28:463-499.
12. Das U.N. A radical approach to cancer. Med Sci Monit 2002, 8:RA79-92.
13. Toyokuni S., Okamoto K., Yodoi J., Hiai H. Persistent oxidative stress in cancer. FEBS Lett 1995, 358:1-3.
14. Halliwell B. Biochemestry of oxidative stress. Biochem Soc Trans 2007, 35:1147-1150.
15. Halliwell B. Free radicals, antioxidants, and human disease: curiosity cause, or consequence. Lancet 1994, 344:721-724.
16. Cooke M.S., Evans M.D., Dizdaroglu M., Lunec J. Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J 2003, 17:1195-1214.
17. Behrend L., Henderson G., Zwacka R.M. Reactive oxygen species in oncogenic transformation. Biochem Soc Trans 2003, 31:1441-1444.
18. Visconti R., Grieco D. New insights on oxidative stress in cancer. Curr Opin Drug Discov Devel 2009, 12:240-245.
19. Conklin K.A. Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr Cancer Ther 2004, 3:294-300.
20. Ozben T. Oxidative stress and apoptosis: impact on cancer therapy. J Pharm Sci 2007, 96:2181-2196.
21. Wang J., Yi J. Cancer cell killing via ROS: to increase or decrease, that is the question. Cancer Biol Ther 2008, 7:1875-1884.
22. Nowsheen S., Wukovich R.L., Aziz K., et al. Accumulation of oxidatively induced clustered DNA lesions in human tumor tissues. Mutat Res 2009, 674:131-136.
23. Hussien M.M.I., McNulty H., Armstrong N., Johnston P.G., Spence R.A.J., Barnett Y. Investigation of systemic folate status, impact of alcohol intake and levels of DNA damage in mononuclear cells of breast cancer patients. Br J Cancer 2005, 92:1524-1530.
24. Sener D.E., Gönenç A., Akinci M., Torun M. Lipid peroxidation and total antioxidant status in patients with breast cancer. Cell Biochem Funct 2007, 25:377-382.
25. Battino M., Bullon P., Wilson M., Newman H. Oxidative injury and inflammatory periodontal diseases: the challenge of anti-oxidants to free radicals and reactive oxygen species. Crit Rev Oral Biol Med 1999, 10:458-476.
26. 2 formation. Free Radic Biol Med 2007, 42:1465-1469.
27. Gutteridge J.M.C., Halliwell B. Free radicals and antioxidants in the year 2000. A historical look to the future. Ann NY Acad Sci 2000, 899:136-147.
28. Ott M., Gogvadze V., Orrenius S., Zhivotovsky B. Mitochondria, oxidative stress and cell death. Apoptosis 2007, 12:913-922.
29. Sjödin B., Hellsten Westing Y., Apple F.S. Biochemical mechanisms for oxygen free radical formation during exercise. Sports Med 1990, 10:236-254.
30. St-Pierre J., Buckingham J.A., Roebuck S.J., Brand M.D. Topology of superoxide production from different sites in the mitochondrial electron transport chain. J Biol Chem 2002, 277:44784-44790.
31. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 2002, 82:47-95.
32. Kim C., Kim J.Y., Kim J.H. Cytosolic phospholipase A(2), lipoxygenase metabolites, and reactive oxygen species. BMB Rep 2008, 41:555-559.
33. Takeya R., Ueno N., Sumimoto H. Regulation of superoxide-producing NADPH oxidases in nonphagocytic cells. Methods Enzymol 2006, 406:456-468.
34. Wolin M.S. Reactive oxygen species and the control of vascular function. Am J Physiol Heart Circ Physiol 2009, 296:H539-H549.
35. Dupuy C., Ohayon R., Valent A., Noël-Hudson M.S., Dème D., Virion A. Purification of a novel flavoprotein involved in the thyroid NADPH oxidase. Cloning of the porcine and human cDNAs. J Biol Chem 1999, 274:37265-37269.
36. He L., Dinger B., Gonzalez C., Obeso A., Fidone S. Function of NADPH oxidase and signaling by reactive oxygen species in rat carotid body type I cells. Adv Exp Med Biol 2006, 580:155-160.
37. Klauning J.E., Kamendulis L.M. The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol 2004, 44:239-267.
38. Gutteridge J.M.C. Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clin Chem 1995, 42:1819-1828.
39. Cejas P., Casado E., Belda-Iniesta C., et al. Implications of oxidative stress and cell membrane lipid peroxidation in human cancer (Spain). Cancer Causes Control 2004, 15:707-719.
40. Marnett L.J. Oxyradicals and DNA damage. Carcinogenesis 2000, 21:361-370.
41. Coskun C., Kural A., Döventas Y., et al. Hemodialysis and protein oxidation products. Ann NY Acad Sci 2007, 1100:404-408.
42. Roy A., Sen S., Chakraborti A.S. In vitro nonenzymatic glycation enhances the role of myoglobin as a source of oxidative stress. Free Radic Res 2004, 38:139-146.
43. Hwang E., Bowen P.E. DNA damage, a biomarker of carcinogenesis: its measurement and modulation by diet and environment. Crit Rev Food Sci Nutr 2007, 47:27-50.
44. Nakabeppu Y., Sakumi K., Sakamoto K., Tsuchimoto D., Tsuzuki T., Nakatsu Y. Mutagenesis and carcinogenesis caused by the oxidation of nucleic acids. Biol Chem 2006, 387:373-379.
45. Liehr J.G., Roy D. Free radical generation by redox cycling of estrogens. Free Radic Biol Med 1990, 8:415-423.
46. Sarabia S.F., Zhu B.T., Kurosawa T., Tohma M., Liehr J.G. Mechanism of cytochrome P450-catalyzed aromatic hydroxylation of estrogens. Chem Res Toxicol 1997, 10:767-771.
47. Markides C.S., Roy D., Liehr J.G. Concentration dependence of prooxidant and antioxidant properties of catecholestrogens. Arch Biochem Biophys 1998, 360:105-112.
48. Santen R., Cavalieri E., Rogan E., et al. Estrogen mediation of breast tumor formation involves estrogen receptor-dependent, as well as independent, genotoxic effects. Ann NY Acad Sci 2009, 1155:132-140.
49. Bolton J.L., Thatcher G.R. Potential mechanisms of estrogen quinone carcinogenesis. Chem Res Toxicol 2008, 21:93-101.
50. Roy D., Cai Q., Felty Q., Narayan S. Estrogen-induced generation of reactive oxygen and nitrogen species, gene damage, and estrogen-dependent cancers. J Toxicol Environ Health B Crit Rev 2007, 10:235-257.
51. Felty Q., Roy D. Estrogen, mitochondria, and growth of cancer and non-cancer cells. J Carcinog 2005, 4:1.
52. Felty Q., Xiong W.C., Sun D., et al. Estrogen-induced mitochondrial reactive oxygen species as signal-transducing messengers. Biochemistry 2005, 44:6900-6909.
53. Parkash J., Felty Q., Roy D. Differential regulation of high and low capacity mitochondrial calcium in breast cancer. Proc Am Assoc Cancer Res 2004, 44:715.
54. Zimmerman R., Cerutti P. Active oxygen acts as a promoter of transformation in mouse embryo C3H/10T1/2/C18 fibroblasts. Proc Natl Acad Sci USA 1984, 81:2085-2087.
55. Sentman M.L., Granström M., Jakobson H., Reaume A., Basu S., Marklund S.L. Phenotypes of mice lacking extracellular superoxide dismutase and copper- and zinc-containing superoxide dismutase. J Biol Chem 2006, 281:6904-6909.
56. Chu F.F., Esworthy R.S., Chu P.G., et al. Bacteria-induced intestinal cancer in mice with disrupted Gpx1 and Gpx2 genes. Cancer Res 2004, 64:962-968.
57. Neumann C.A., Krause D.S., Carman C.V., et al. Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defense and tumour suppression. Nature 2003, 424:561-565.
58. Ishii K., Zhen L.X., Wang D.H., Funamori Y., Ogawa K., Taketa K. Prevention of mammary tumorigenesis in acatalasemic mice by vitamin E supplementation. Jpn J Cancer Res 1996, 87:680-684.
59. Gosselin K., Martien S., Pourtier A., et al. Senescence-associated oxidative DNA damage promotes the generation of neoplastic cells. Cancer Res 2009, 69:7917-7925.
60. Laurent A., Nicco C., Chéreau C., et al. Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res 2005, 65:948-956.
61. Trush M.A., Kensler T.W. An overview of the relationship between oxidative stress and chemical carcinogenesis. Free Radic Biol Med 1991, 10:201-209.
62. Valko M., Rhodes C.J., Moncol J., Izakovic M., Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 2006, 44:1-40.
63. Halliwell B. Oxidative stress and cancer: have we moved forward?. Biochem J 2007, 401:1-11.
64. Barzilai A., Rotman G., Shiloh Y. ATM deficiency and oxidative stress: a new dimension of defective response to DNA damage. DNA Repair (Amst) 2002, 1:3-25.
65. Kopnin P.B., Agapova L.S., Kopnin B.P., Chumakov P.M. Repression of sestrin family genes contributes to oncogenic Ras-induced reactive oxygen species up-regulation and genetic instability. Cancer Res 2007, 67:4671-4678.
66. Jackson J.H. Potential molecular mechanisms of oxidant-induced carcinogenesis. Environ Health Perspect 1994, 102:155-157.
67. Ruiz-Ramos R., Lopez-Carrillo L., Rios-Perez A.D., De Vizcaya-Ruíz A., Cebrian M.E. Sodium arsenite induces ROS generation, DNA oxidative damage, HO-1 and c-Myc proteins, NF-kappaB activation and cell proliferation in human breast cancer MCF-7 cells. Mutat Res 2009, 674:109-115.
68. Slater A.F., Stefan C., Nobel I., van den Dobbelsteen D.J., Orrenius S. Signalling mechanisms and oxidative stress in apoptosis. Toxicol Lett 1995, 82-83:149-153.
69. Vaquero E.C., Edderkaoui M., Pandol S.J., Gukovsky I., Gukovskaya A.S. Reactive oxygen species produced by NAD(P)H oxidase inhibit apoptosis in pancreatic cancer cells. J Biol Chem 2004, 279:34643-34654.
70. Groeger G., Mackey A.M., Pettigrew C.A., Bhatt L., Cotter T.G. Stress-induced activation of Nox contributes to cell survival signalling via production of hydrogen peroxide. J Neurochem 2009, 109:1544-1554.
71. Urbano A., Lakshmanan U., Choo P.H., et al. AIF suppresses chemical stress-induced apoptosis and maintains the transformed state of tumor cells. EMBO J 2005, 24:2815-2826.
72. + exchanger 1 gene expression connects intracellular redox status with cells' sensitivity to death triggers. Cell Death Differ 2006, 13:628-641.
73. Kwon J., Lee S.R., Yang K.S., et al. Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors. Proc Natl Acad Sci USA 2004, 101:16419-16424.
74. Hofseth L.J., Saito S., Hussain S.P., et al. Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc Natl Acad Sci USA 2003, 100:143-148.
75. Szabó C., Ohshima H. DNA damage induced by peroxynitrite: subsequent biological effects. Nitric Oxide 1997, 1:373-385.
76. Trueba G.P., Sánchez G.M., Giuliani A. Oxygen free radical and antioxidant defense mechanism in cancer. Front Biosci 2004, 9:2029-2044.
77. Klinge J.M., Topf H.G., Trusen B., Rauh M., Rascher W., Dötsch J. Endothelial cells play an important role in the antiaggregatory effect of nitric oxide. Crit Care Med 2003, 31:2010-2014.
78. 2-mediated oxidation and inactivation of phosphatases in growth factor signaling. Proc Natl Acad Sci USA 2008, 105:7147-7152.
79. Burdick A.D., Davis J.W., Liu K.J., et al. Benzo(a)pyrene quinones increase cell proliferation, generate reactive oxygen species, and transactivate the epidermal growth factor receptor in breast epithelial cells. Cancer Res 2003, 63:7825-7833.
80. DeYulia G.J., Cárcamo J.M. EGF receptor-ligand interaction generates extracellular hydrogen peroxide that inhibits EGFR-associated protein tyrosine phosphatases. Biochem Biophys Res Commun 2005, 334:38-42.
81. Finch J.S., Tome M.E., Kwei K.A., Bowden G.T. Catalase reverses tumorigenicity in a malignant cell line by an epidermal growth factor receptor pathway. Free Radic Biol Med 2006, 40:863-875.
82. Bae Y.S., Sung J.Y., Kim O.S., et al. Platelet-derived growth factor-induced H(2)O(2) production requires the activation of phosphatidylinositol 3-kinase. J Biol Chem 2000, 275:10527-10531.
83. Lin C.W., Yang L.Y., Shen S.C., Chen Y.C. IGF-I plus E2 induces proliferation via activation of ROS-dependent ERKs and JNKs in human breast carcinoma cells. J Cell Physiol 2007, 212:666-674.
84. Ushio-Fukai M., Nakamura Y. Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Lett 2008, 266:37-52.
85. Harris S.R., Schoeffner D.J., Yoshiji H., Thorgeirsson U.P. Tumor growth enhancing effects of vascular endothelial growth factor are associated with increased nitric oxide synthase activity and inhibition of apoptosis in human breast carcinoma xenografts. Cancer Lett 2002, 179:95-101.
86. Xia C., Meng Q., Liu L.Z., Rojanasakul Y., Wang X.R., Jiang B.H. Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. Cancer Res 2007, 67:10823-10830.
87. Arbiser J.L., Petros J., Klafter R., et al. Reactive oxygen generated by Nox1 triggers the angiogenic switch. Proc Natl Acad Sci USA 2002, 99:715-720.
88. Storz P. Reactive oxygen species in tumor progression. Front Biosci 2005, 10:1881-1896.
89. Lüpertz R., Chovolou Y., Kampkötter A., Wätjen W., Kahl R. Catalase overexpression impairs TNF-alpha induced NF-kappaB activation and sensitizes MCF-7 cells against TNF-alpha. J Cell Biochem 2008, 103:1497-1511.
90. Roy D., Sarkar S., Felty Q. Levels of IL-1 beta control stimulatory/inhibitory growth of cancer cells. Front Biosci 2006, 11:889-898.
91. Xue L., Pestka J.J., Li M., Firestone G.L., Bjeldanes L.F. 3,3'-Diindolylmethane stimulates murine immune function in vitro and in vivo. J Nutr Biochem 2008, 19:336-344.
92. Seidelin J.B., Nielsen O.H. Continuous cytokine exposure of colonic epithelial cells induces DNA damage. Eur J Gastroenterol Hepatol 2005, 17:363-369.
93. Zhou Q., Liu L.Z., Fu B., et al. Reactive oxygen species regulate insulin-induced VEGF and HIF-1alpha expression through the activation of p70S6K1 in human prostate cancer cells. Carcinogenesis 2007, 28:28-37.
94. Liu L.Z., Hu X.W., Xia C., et al. Reactive oxygen species regulate epidermal growth factor-induced vascular endothelial growth factor and hypoxia-inducible factor-1alpha expression through activation of AKT and P70S6K1 in human ovarian cancer cells. Free Radic Biol Med 2006, 41:1521-1533.
95. Nakai K., Yoneda K., Igarashi J., Moriue T., Kosaka H., Kubota Y. Angiotensin II enhances EGF receptor expression levels via ROS formation in HaCaT cells. J Dermatol Sci 2008, 51:181-189.
96. 2, a necessary evil for cell signaling. Science 2006, 12:1882-1883.
97. Boivin B., Zhang S., Arbiser J.L., Zhang Z.Y., Tonks N.K. A modified cysteinyl-labeling assay reveals reversible oxidation of protein tyrosine phosphatases in angiomyolipoma cells. Proc Natl Acad Sci USA 2008, 105:9959-9964.
98. Bae Y.S., Kang S.W., Seo M.S., et al. Epidermal growth factor (EGF)-induced generation of hydrogen peroxide. Role in EGF receptor-mediated tyrosine phosphorylation. J Biol Chem 1997, 272:217-221.
99. Roy D., Felty Q., Slingerland J.M., Garba N.A., Penny R., Koh V. Reversible inactivation of CDC25A by estrogen and antiestrogens-induced reactive oxygen species may be involved in the phosphorylatopn of P27. Era of Hope meeting 2008, Abstract BC060125-1. Available at https://www.cdmrpcures.org.
100. Wang Z., Zhang B., Wang M., Carr B.I. Cdc25A and ERK interaction: EGFR-independent ERK activation by a protein phosphatase Cdc25A inhibitor, compound 5. J Cell Physiol 2005, 204:437-444.
101. McCubrey J.A., Steelman L.S., Abrams S.L., et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 2006, 46:249-279.
102. Ingley E., Klinken S.P. Cross-regulation of JAK and Src kinases. Growth Factors 2006, 4:89-95.
103. Stacey D.W. Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. Curr Opin Cell Biol 2003, 15:158-163.
104. Irani K., Xia Y., Zweier J.L., et al. Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science 1997, 275:1649-1652.
105. Sarsour E.H., Venkataraman S., Kalen A.L., Oberley L.W., Goswami P.C. Manganese superoxide dismutase activity regulates transitions between quiescent and proliferative growth. Aging Cell 2008, 7:405-417.
106. Menon S.G., Sarsour E.H., Kalen A.L., et al. Superoxide signaling mediates N-acetyl-l-cysteine-induced G1 arrest: regulatory role of cyclin D1 and manganese superoxide dismutase. Cancer Res 2007, 67:6392-6399.
107. Lim J.H., Lee Y.M., Chun Y.S., Park J.W. Reactive oxygen species-mediated cyclin D1 degradation mediates tumor growth retardation in hypoxia, independently of p21cip1 and hypoxia-inducible factor. Cancer Sci 2008, 99:1798-1805.
108. Menon S.G., Coleman M.C., Walsh S.A., Spitz D.R., Goswami P.C. Differential susceptibility of nonmalignant human breast epithelial cells and breast cancer cells to thiol antioxidant-induced G(1)-delay. Antioxid Redox Signal 2005, 7:711-718.
109. Adler V., Yin Z., Tew K.D., Ronai Z. Role of redox potential and reactive oxygen species in stress signaling. Oncogene 1999, 18:6104-6111.
110. Adachi Y., Shibai Y., Mitsushita J., Shang W.H., Hirose K., Kamata T. Oncogenic Ras upregulates NADPH oxidase 1 gene expression through MEK-ERK-dependent phosphorylation of GATA-6. Oncogene 2008, 27:4921-4932.
111. Cuenda A., Rosseau S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta 2007, 1773:1358-1375.
112. Dolado I., Swat A., Ajenjo N., De Vita G., Cuadrado A., Nebreda A.R. p38alpha MAP kinase as a sensor of reactive oxygen species in tumorigenesis. Cancer Cell 2007, 11:191-205.
113. 2-induced cell death via coordinated regulation of stress kinases. Cancer Res 2000, 60:4053-4057.
114. Sancho R., Nateri A.S., de Vinuesa A.G., et al. JNK signalling modulates intestinal homeostasis and tumourigenesis in mice. EMBO J 2009, 28:1843-1854.
115. Nielsen C., Thastrup J., Bøttzauw T., Jäättelä M., Kallunki T. c-Jun NH2-terminal kinase 2 is required for Ras transformation independently of activator protein 1. Cancer Res 2007, 67:178-185.
116. Lee R.J., Albanese C., Stenger R.J., et al. pp60(v-src) induction of cyclin D1 requires collaborative interactions between the extracellular signal-regulated kinase, p38, and Jun kinase pathways. A role for cAMP response element-binding protein and activating transcription factor-2 in pp60(v-src) signaling in breast cancer cells. J Biol Chem 1999, 274:7341-7350.
117. Ali A.S., Ali S., El-Rayes B.F., Philip P.A., Sarkar F.H. Exploitation of protein kinase C: a useful target for cancer therapy. Cancer Treat Rev 2009, 35:1-8.
118. 2-stimulated cells. J Biochem 2008, 143:31-38.
119. Min D.S., Ahn B.H., Jo Y.H. Differential tyrosine phosphorylation of phospholipase D isozymes by hydrogen peroxide and the epidermal growth factor in A431 epidermoid carcinoma cells. Mol Cells 2001, 11:369-378.
120. Bai X.C., Deng F., Liu A.L., et al. Phospholipase C-gamma1 is required for cell survival in oxidative stress by protein kinase C. Biochem J 2002, 363:395-401.
121. Parsons S.J., Parsons J.T. Src family kinases, key regulators of signal transduction. Oncogene 2004, 23:7906-7909.
122. Minetti M., Mallozzi C., Di Stasi A.M. Peroxynitrite activates kinases of the src family and upregulates tyrosine phosphorylation signaling. Free Radic Biol Med 2002, 33:744-754.
123. Nakamura K., Hori T., Sato N., Sugie K., Kawakami T., Yodoi J. Redox regulation of a src family protein tyrosine kinase p56lck in T cells. Oncogene 1993, 8:3133-3139.
124. Redondo P.C., Salido G.M., Pariente J.A., Rosado J.A. Dual effect of hydrogen peroxide on store-mediated calcium entry in human platelets. Biochem Pharmacol 2004, 67:1065-1076.
125. Giannoni E., Buricchi F., Grimaldi G., et al. Redox regulation of anoikis: reactive oxygen species as essential mediators of cell survival. Cell Death Differ 2008, 15:867-878.
126. Kemble D.J., Sun G. Direct and specific inactivation of protein tyrosine kinases in the Src and FGFR families by reversible cysteine oxidation. Proc Natl Acad Sci USA 2009, 106:5070-5075.
127. Karin M., Takahashi T., Kapahi P., et al. Oxidative stress and gene expression: the AP-1 and NF-κB connections. Biofactors 2001, 15:87-89.
128. Anderson E. The role of oestrogens and progesterone receptors in human mammary development and tumorigenesis. Breast Cancer Res 2002, 4:197-201.
129. Song R.X., Santen R.J. Membrane initiated estrogen signalling breast cancer. Biol Reprod 2006, 75:9-16.
130. Tamir S., Izrael S., Vaya J. The effect of oxidative stress on ERalpha and ERbeta expression. J Steroid Biochem Mol Biol 2002, 81:327-332.
131. Whittal R.M., Benz C.C., Scott G., Semyonov J., Burlingame A.L., Baldwin M.A. Preferential oxidation of zinc finger 2 in estrogen receptor DNA-binding domain prevents dimerization and, hence, DNA binding. Biochemistry 2000, 39:8406-8417.
132. Weitsman G.E., Weebadda W., Ung K., Murphy L.C. Reactive oxygen species induce phosphorylation of serine 118 and 167 on estrogen receptor alpha. Breast Cancer Res Treat 2009, 118:269-279.
133. Mandlekar S., Kong A.N. Mechanisms of tamoxifen-induced apoptosis. Apoptosis 2001, 6:469-477.
134. Cui Y., Parra I., Zhang M., et al. Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. Cancer Res 2006, 66:5950-5959.
135. Surh Y.J., Kundu J.K., Na H.K. Nrf2 as a master redox switch in turning on the cellular signaling involved in the induction of cytoprotective genes by some chemopreventive phytochemicals. Planta Med 2008, 74:1526-1539.
136. Kwak M.K., Wakabayashi N., Kensler T.W. Chemoprevention through the Keap1-Nrf2 signaling pathway by phase 2 enzyme inducers. Mutat Res 2004, 555:133-148.
137. Ramos-Gomez M., Dolan P.M., Itoh K., Yamamoto M., Kensler T.W. Interactive effects of nrf2 genotype and oltipraz on benzo[a]pyrene-DNA adducts and tumor yield in mice. Carcinogenesis 2003, 24:461-467.
138. Wang X.J., Sun Z., Villeneuve N.F., et al. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 2008, 29:1235-1243.
139. Meijerman I., Beijnen J.H., Schellens J.H. Combined action and regulation of phase II enzymes and multidrug resistance proteins in multidrug resistance in cancer. Cancer Treat Rev 2008, 34:505-520.
140. Angel P., Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1991, 1072:129-157.
141. Wisdom R. AP-1: one switch for many signals. Exp Cell Res 1999, 253:180-185.
142. Pinkus R., Weiner L.M., Daniel V. Role of oxidants and antioxidants in the induction of AP-1, NF-kappaB, and glutathione S-transferase gene expression. J Biol Chem 1996, 271:13422-13429.
143. Hsu T.C., Young M.R., Cmarik J., Colburn N.H. Activator protein 1 (AP-1) and nuclear factor kappaB (NF-kappaB)-dependent transcriptional events in carcinogenesis. Free Radic Biol Med 2000, 28:1338-1348.
144. Wu J.T., Kral J.G. The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy. J Surg Res 2005, 123:158-169.
145. Takada Y., Mukhopadhyay A., Kundu G.C., Mahabeleshwar G.H., Singh S., Aggarwal B.B. Hydrogen peroxide activates NF-kappa B through tyrosine phosphorylation of I kappa B alpha and serine phosphorylation of p65: evidence for the involvement of I kappa B alpha kinase and Syk protein-tyrosine kinase. J Biol Chem 2003, 278:24233-24241.
146. Janssen-Heininger Y.M., Poynter M.E., Baeuerle P.A. Recent advances towards understanding redox mechanisms in the activation of nuclear factor kappaB. Free Radic Biol Med 2000, 28:1317-1327.
147. Li J.J., Westergaard C., Ghosh P., Colburn N.H. Inhibitors of both nuclear factor-kappaB and activator protein-1 activation block the neoplastic transformation response. Cancer Res 1997, 57:3569-3576.
148. Stein B., Baldwin A.S., Ballard D.W., Greene W.C., Angel P., Herrlich P. Cross-coupling of the NF-kappa B p65 and Fos/Jun transcription factors produces potentiated biological function. EMBO J 1993, 12:3879-3891.
149. Fujioka S., Niu J., Schmidt C., et al. NF-kappaB and AP-1 connection: mechanism of NF-kappaB-dependent regulation of AP-1 activity. Mol Cell Biol 2004, 24:7806-7819.
150. Chandel N.S., Simon M.C. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1α during hypoxia. J Biol Chem 2000, 275:25130-25138.
151. Kizaka-Kondoh S., Tanaka S., Harada H., Hiraoka M. The HIF-1-active microenvironment: an environmental target for cancer therapy. Adv Drug Deliv Rev 2009, 61:623-632.
152. Pialoux V., Mounier R., Brown A.D., Steinback C.D., Rawling J.M., Poulin M.J. Relationship between oxidative stress and HIF-1 alpha mRNA during sustained hypoxia in humans. Free Radic Biol Med 2009, 46:321-326.
153. Kimbro K.S., Simons J.W. Hipoxia-inducible factor-1 in human breast and prostate cancer. Endocr Relat Cancer 2006, 13:739-749.
154. Lim J.H., Lee E.S., You H.J., Lee J.W., Park J.W., Chun Y.S. Ras-dependent induction of HIF-1alpha785 via the Raf/MEK/ERK pathway: a novel mechanism of Ras-mediated tumor promotion. Oncogene 2004, 23:9427-9431.
155. Brown N.S., Bicknell R. Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res 2001, 3:323-327.
156. Peng X.H., Karna P., Cao Z., Jiang B.H., Zhou M., Yang L. Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1a signal pathways increases resistance to apoptosis by up-regulating Survivin gene expression. J Biol Chem 2006, 281:25903-25914.
157. Bos R., Zhong H., Hanrahan C.F., et al. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 2001, 93:309-314.
158. Maxwell P.H., Dachs G.U., Gleadle J.M., et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 1997, 94:8104-8109.
159. North S., Moenner M., Bikfalvi A. Recent developments in the regulation of the angiogenic switch by cellular stress factors in tumors. Cancer Lett 2005, 218:1-14.
160. Shojaei F., Ferrara N. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. Drug Resist Updat 2008, 11:219-230.
161. Harlozinska A. Progress in molecular mechanisms of tumor metastasis and angiogenesis. Anticancer Res 2005, 25:3327-3333.
162. Wendt M.K., Schiemann W.P. Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis. Breast Cancer Res 2009, 11:R68.
163. Parsons M., Keppler M.D., Kline A., et al. Site-directed perturbation of protein kinase C-integrin interaction blocks carcinoma cell chemotaxis. Mol Cell Biol 2002, 22:5897-5911.
164. Wei Y.Y., Chen Y.J., Hsiao Y.C., Huang Y.C., Lai T.H., Tang C.H. Osteoblasts-derived TGF-beta1 enhance motility and integrin upregulation through Akt, ERK, and NF-kappaB-dependent pathway in human breast cancer cells. Mol Carcinog 2008, 47:526-537.
165. Gilcrease M.Z., Zhou X., Welch K. Adhesion-independent alpha6beta4 integrin clustering is mediated by phosphatidylinositol 3-kinase. Cancer Res 2004, 64:7395-7398.
166. Karlsson R., Pedersen E.D., Wang Z., Brakebusch C. Rho GTPase function in tumorigenesis. Biochim Biophys Acta 2009, 1796:91-98.
167. Nimnual A.S., Taylor L.J., Bar-Sagi D. Redox-dependent downregulation of Rho by Rac. Nat Cell Biol 2003, 5:236-241.
168. Mori K., Shibanuma M., Nose K. Invasive potential induced under long-term oxidative stress in mammary epithelial cells. Cancer Res 2004, 64:7464-7472.
169. Huot J., Houle F., Marceau F., Landry J. Oxidative stress-induced actin reorganization mediated by the p38 mitogen-activated protein kinase/heat shock protein 27 pathway in vascular endothelial cells. Circ Res 1997, 80:383-392.
170. Chabottaux V., Noel A. Breast cancer progression: insights into multifaceted matrix metalloproteinases. Clin Exp Metastasis 2007, 24:647-656.
171. McGowan P.M., Duffy M.J. Matrix metalloproteinase expression and outcome in patients with breast cancer: analysis of a published database. Ann Oncol 2008, 19:1566-1572.
172. Li H.C., Cao D.C., Liu Y., et al. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res Treat 2004, 88:75-85.
173. Rajagopalan S., Meng X.P., Ramasamy S., Harrison D.G., Galis Z.S. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest 1996, 98:2572-2579.
174. Swaim M.W., Pizzo S.V. Methionine sulfoxide and the oxidative regulation of plasma proteinase inhibitors. J Leukoc Biol 1998, 43:365-379.
175. Nelson K.K., Melendez J.A. Mitochondrial redox control of matrix metalloproteinases. Free Radic Biol Med 2004, 37:768-784.
176. Kakarala M., Wicha M.S. Cancer stem cell: implications for cancer treatment and prevention. Cancer J 2007, 13:271-275.
177. Mimeault M., Hauke R., Mehta P.P., Batra S.K. Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J Cell Mol Med 2007, 11:981-1011.
178. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100:3983-3988.
179. Korkaya H., Wicha M.S. Selective targeting of cancer stem cells. A new concept in cancer therapeutics. BioDrugs 2007, 21:299-300.
180. Kimura A., Ohmori T., Ohkawa R., et al. Essential roles of sphingosine 1-phosphate/S1P1 receptor axis in the migration of neural stem cells toward a site of spinal cord injury. Stem Cells 2007, 25:115-124.
181. Imitola J., Raddassi K., Park K.I., et al. Directed migration of neural stem cells to site of CNS injury by the stromal cell-derived factor 1alpha/CXC chemokine receptor 4 pathway. Proc Natl Acad Sci USA 2004, 101:18117-18122.
182. Kucia M., Reca R., Miekus K., et al. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 2005, 23:879-894.
183. Nolan D.J., Ciarrocchi A., Mellick A.S., et al. Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes Dev 2007, 21:1546-1558.
184. Das B., Tsuchida R., Malkin D., Koren G., Baruchel S., Yeger H. Hypoxia enhances tumor stemness by increasing the invasive and tumorigenic side population fraction. Stem Cells 2008, 26:1818-1830.
185. Hosokawa K., Arai F., Yoshihara H., et al. Function of oxidative stress in the regulation of hematopoietic stem cell-niche interaction. Biochem Biophys Res Commun 2007, 363:578-583.
186. Ito K., Hirao A., Arai F., et al. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat Med 2006, 12:446-451.
187. Lévesque J.P., Winkler I.G., Hendy J., et al. Hematopoietic progenitor cell mobilization results in hypoxia with increased hypoxia-inducible transcription factor-1 alpha and vascular endothelial growth factor A in bone marrow. Stem Cells 2007, 25:1954-1965.
188. Heffron C.C., Gallagher M.F., Guenther S., et al. Global mRNA analysis to determine a transcriptome profile of cancer stemness in a mouse model. Anticancer Res 2007, 27:1319-1324.
189. Diehn M., Cho R.W., Lobo N.A., et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009, 458:780-783.
190. Riley P.A. Free radicals in biology: oxidative stress and the effects of ionizing radiation. Int J Radiat Biol 1994, 65:27-33.
191. Kattan Z., Minig V., Leroy P., Dauça M., Becuwe P. Role of manganese superoxide dismutase on growth and invasive properties of human estrogen-independent breast cancer cells. Breast Cancer Res Treat 2008, 108:203-215.
192. Policastro L., Molinari B., Larcher F., et al. Imbalance of antioxidant enzymes in tumor cells and inhibition of proliferation and malignant features by scavenging hydrogen peroxide. Mol Carcinog 2004, 39:103-113.
193. Mena S., Benlloch M., Ortega A., et al. Bcl-2 and glutathione depletion sensitizes B16 melanoma to combination therapy and eliminates metastatic disease. Clin Cancer Res 2007, 13:2658-2666.
194. Ortega A., Ferrer P., Carretero J., et al. Down-regulation of glutathione and Bcl-2 synthesis in mouse B16 melanoma cells avoids their survival during interaction with the vascular endothelium. J Biol Chem 2003, 278:39591-39599.
195. Donaldson M.S. Nutrition and cancer: a review of the evidence for an anti-cancer diet. Nutr J 2004, 3:19-40.
196. van Gils C.H., Peeters P.H., Bueno-de-Mesquita H.B., et al. Consumption of vegetables and fruits and risk of breast cancer. JAMA 2005, 293:183-193.
197. Michels K.B., Mohllajee A.P., Roset-Bahmanyar E., Beehler G.P., Moysich K.B. Diet and breast cancer. A review of the prospective observational studies. Cancer 2007, 109:2712-2749.
198. Aggarwal B.B., Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 2006, 71:1397-1421.
199. Nicolson G.L., Conklin K.A. Reversing mitochondrial dysfunction, fatigue and the adverse effects of chemotherapy of metastatic disease by molecular replacement therapy. Clin Exp Metastasis 2008, 25:161-169.
200. Block K.I., Koch A.C., Mead M.N., Tothy P.K., Newman R.A., Gyllenhaal C. Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Int J Cancer 2008, 123:1227-1239.
201. D'Andrea G.M. Use of antioxidants during chemotherapy and radiotherapy should be avoided. CA Cancer J Clin 2005, 55:319-321.
202. Pathak A.K., Bhutani M., Guleria R., et al. Chemotherapy alone vs. chemotherapy plus high dose multiple antioxidants in patients with advanced non small cell lung cancer. J Am Coll Nutr 2005, 24:16-21.
203. Fang J., Seki T., Maeda H. Therapeutic strategies by modulating oxygen stress in cancer and inflammation. Adv Drug Deliv Rev 2009, 61:290-302.
204. Guzman M.L., Li X., Corbett C.A., et al. Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8). Blood 2007, 110:4436-4444.
205. Fang J., Nakamura H., Iyer A.K. Tumor-targeted induction of oxystress for cancer therapy. J Drug Target 2007, 15:475-486.
206. Crouse D.L., Goldberg M.S., Ross N.A., Chen H., Labrèche F. Postmenopausal breast cancer is associated with exposure to traffic-related air pollution in Montreal, Canada: a Case-Control Study. Environ Health Perspect 2010, 118:1578-1583.